危重婴儿基因组医学研究中的效用测量:一项系统评价
该研究为系统评价,纳入21项前瞻性全文研究、共1654例危重婴儿,评估全外显子与全基因组测序的效用测量方式。结果显示平均46%(范围15%-72%)患者遗传检测阳性,平均37%(范围13%-61%)符合效用标准;研究创建了包含治疗改变、照护方向调整、预后信息、生殖信息及筛查/专科转诊5类的标准化效用框架。多数研究遗漏个人效用(20项[95%])、阴性或不确定结果效用(15项[71%])及危害(20项[95%]),且不成比例地突出导致治疗改变的病例。研究规模与效用呈负相关(r=-0.65;P=.002),提示需更完整定义以理解遗传医学的潜在获益与危害。
要点
- 系统评价纳入21项前瞻性研究、1654例危重婴儿,平均46%(15%-72%)遗传检测阳性,平均37%(13%-61%)符合效用标准。
- 研究建立5类效用框架:治疗改变、照护方向调整、预后信息、生殖信息、筛查或专科转诊。
- 20项研究(95%)遗漏个人效用(患者报告获益),15项(71%)遗漏阴性或不确定结果效用,20项(95%)遗漏危害。
- 研究规模与效用负相关(r=-0.65;P=.002),较大研究报告的效用显著较低。
- 作者认为更完整且一致使用的效用定义可能改善对遗传医学潜在获益与危害的理解。
适用人群与场景
- 纳入标准:危重婴儿(小于1岁)的全外显子或全基因组测序的前瞻性全文研究。
- 场景:危重婴儿的基因组医学研究,未限定具体急诊或ICU场景。
诊断标准与关键阈值
- 效用标准化框架包含5类:治疗改变、照护方向调整、预后信息、生殖信息、筛查或专科转诊。
研究设计与关键结果
- 研究类型:系统评价,检索PubMed、Embase、Scopus、Cochrane Library、Cochrane系统评价数据库及ClinicalTrials.gov,自建库至2022年5月,英文限制。
- 样本量:21项研究,共1654例患者。
- 主要结果:平均46%(范围15%-72%)患者遗传检测阳性;平均37%(范围13%-61%)符合效用标准。
- 效用测量异质性下创建5类标准化框架:治疗改变、照护方向调整、预后信息、生殖信息、筛查或专科转诊。
- 缺失情况:20项研究(95%)遗漏个人效用,15项(71%)遗漏阴性或不确定结果效用,20项(95%)遗漏危害。
- 研究规模与效用负相关:r=-0.65;P=.002。
证据类型、等级与局限
- 证据类型:系统评价。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,更完整且一致使用的效用定义可能改善对遗传医学潜在获益与危害的理解。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Genomic medicine holds promise to revolutionize care for critically ill infants by tailoring treatments for patients and providing additional prognostic information to families. However, measuring the utility of genomic medicine is not straightforward and has important clinical and ethical implications.
OBJECTIVE: To review the ways that researchers measure or neglect to measure the utility of genomic medicine for critically ill infants.
EVIDENCE REVIEW: This systematic review included prospective full-text studies of genomic medicine of both whole exome and genome sequencing in critically ill infants younger than 1 year. PubMed, Embase, Scopus, and Cochrane Library databases, the Cochrane Database of Systematic Reviews, and the ClinicalTrials.gov register were searched with an English language restriction for articles published from the inception of each database through May 2022. Search terms included variations of the following: gene, sequencing, intensive care, critical care, and infant. From the included articles, information on how utility was defined and measured was extracted and synthesized. Information was also extracted from patient cases that authors highlighted by providing additional information. Spearman rank-order correlation was used to evaluate the association between study size and utility.
FINDINGS: Synthesized data from the 21 included studies reflected results from 1654 patients. A mean of 46% (range, 15%-72%) of patients had a positive genetic test result, and a mean of 37% (range, 13%-61%) met the criteria for experiencing utility. Despite heterogeneity in how studies measured and reported utility, a standardized framework was created with 5 categories of utility: treatment change, redirection of care, prognostic information, reproductive information, and screening or subspecialty referral. Most studies omitted important categories of utility, notably personal utility (patient-reported benefits) (20 studies [95%]), utility of negative or uncertain results (15 [71%]), and disutility (harms) (20 [95%]). Studies disproportionally highlighted patient cases that resulted in treatment change. Larger studies reported substantially lower utility (r = -0.65; P = .002).
CONCLUSIONS AND RELEVANCE: This systematic review found that genomic medicine offered various categories of utility for a substantial proportion of critically ill infants. Studies measured utility in heterogeneous ways and focused more on documenting change than assessing meaningful benefit. Authors' decisions about which cases to highlight suggest that some categories of utility may be more important than others. A more complete definition of utility that is used consistently may improve understanding of potential benefits and harms of genetic medicine.
参考来源
- Callahan KP, Mueller R, Flibotte J, et al. Measures of Utility Among Studies of Genomic Medicine for Critically Ill Infants: A Systematic Review. JAMA Netw Open. 2022. PMID: 35947384. doi:10.1001/jamanetworkopen.2022.25980
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。